Returns Breakdown
| Return on Investment | (70.49) | |
| Return on Assets | (0.59) | |
| Return on Equity | (0.76) | |
| Return Capital | (1.13) | |
| Return on Sales | (8.03) |
Estimating Rhythm Pharmaceuticals (USA Stocks:RYTM) price for September 2023.
 | By Nico Santiago | Macroaxis Story |
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a commercial-stage biopharmaceutical company in the healthcare sector, has been showing promising signs of potential upside. As of August 2023, the company's valuation market value stands at $24.32, with a Wall Street target price of $36.89 and an analyst target price estimated value of $37.11. This suggests a significant potential upside from the current naive expected forecast value of $26.15. The company's lead product candidate, IMCIVREE, has been making strides in the treatment of rare genetic diseases of obesity, which could be a key driver of this potential growth. However, investors should also consider the company's EPS estimate for the next year, which indicates a projected loss of $2.46 per share. Furthermore, the company's beta of 1.68 indicates a higher level of volatility compared to the overall market. The short ratio of 11.79 and short percent of 0.336, with 11.5M shares short, suggest a level of skepticism from some investors. Nevertheless, with 5 strong buy recommendations from analysts, the potential upside price of $30.6 could be a realistic target by September 2023. The depreciation, amortization, and accretion of Rhythm Pharmaceuticals is currently very stable, showing a significant contrast to the previous year. Last year, Rhythm Pharmaceuticals reported a depreciation, amortization, and accretion value of $1.67 million. As of August 3, 2023, the net cash flow or change in cash and cash equivalents is projected to increase to approximately $73.8 million. Conversely, average assets are expected to decrease to about $301.3 million. The fundamental reason for this short-term view is to provide an analysis of our Rhythm forecast for insiders. We aim to predict the outlook for Rhythm Pharmaceuticals in September.
Macroaxis uses a strict editorial review process to publish stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.
Reviewed by Vlad Skutelnik
Rhythm Pharmaceuticals (NASDAQ:RYTM), a key player in the biotechnology industry, has shown a promising potential upside of 5.34 by September 2023. Despite a current EPS estimate for the year standing at a loss of 3.23, the company's market risk adjusted performance of 0.2621 and a Sortino Ratio of 0.0883 indicate a potential for positive returns. The stock's beta of 1.6841 suggests it's more volatile than the market, which could mean higher potential returns for risk-tolerant investors. With a last price of 24.32 and a low price of 22.35, the price percent change of 6.9 demonstrates a positive trend. However, investors should be aware of the high standard deviation of 4.63 and a coefficient of variation of 1.2K, indicating significant risk and volatility.
Continued study
Rhythm Pharmaceuticals has a beta of 1.4758. This suggests that the company is likely to outperform the market when it is on an upward trend. Conversely, in the event of negative market returns, Rhythm Pharmaceuticals is expected to underperform. The beta indicator serves as a tool for investors to gauge whether Rhythm Pharmaceuticals' movements align with the overall market, and to assess its volatility (i.e., risk) relative to the market (i.e., selected benchmark). In simpler terms, if Rhythm's performance doesn't deviate significantly from the market, it doesn't contribute much risk to the portfolio, but it also doesn't significantly enhance the anticipated returns.There are currently many different techniques concerning forecasting the market as a whole as well as predicting future values of individual securities such as Rhythm Pharmaceuticals. Regardless of method or technology, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Predictive Modules for Rhythm Pharmaceuticals
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Rhythm Pharmaceuticals' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
How important is Rhythm Pharmaceuticals's Liquidity
Rhythm Pharmaceuticals financial leverage refers to using borrowed capital as a funding source to finance Rhythm Pharmaceuticals ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Rhythm Pharmaceuticals financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Rhythm Pharmaceuticals' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Rhythm Pharmaceuticals' financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the breakdown between Rhythm Pharmaceuticals's total debt and its cash.
Rhythm Pharmaceuticals Gross Profit
Rhythm Pharmaceuticals Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Rhythm Pharmaceuticals previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Rhythm Pharmaceuticals Gross Profit growth over the last 10 years. Please check Rhythm Pharmaceuticals' gross profit and other fundamental indicators for more details.
Detailed Perspective On Rhythm Pharmaceuticals
The recent price roll up of Rhythm Pharmaceuticals created some momentum for insiders as it was traded today as low as 22.35 and as high as 25.3 per share. The company management teams may have good odds in positioning the company resources to exploit market volatility in September. The stock standard deviation of daily returns for 90 days investing horizon is currently 4.45. This high volatility is attributed to the latest market swings and not-so-good earnings reports for some of the Rhythm Pharmaceuticals partners.
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a biotechnology firm specializing in rare genetic diseases of obesity, has been showing promising potential. Despite having a high Probability Of Bankruptcy at 73.32%, the firm's robust financial health is notable with a Debt to Equity of just 0.011% and a healthy Current Ratio of 5.59X. The company also has a substantial amount of Cash and Equivalents, standing at a whopping $235.6M.Rhythm Pharmaceuticals' shares have seen fluctuations over the past 52 weeks, with a low of $15.5 and a high of $34.99. Despite this volatility, the firm's Potential Upside is at 5.34, indicating potential for growth. The market seems to have faith in this potential, with Shares Owned by Institutions at a massive 99.60%. The firm's Price to Book stands at 5.01X, indicating a higher market valuation compared to its Book Value Per Share of 3.87X. With a Target Price of $36.89, there is potential for significant upside from the current trading levels. However, investors should also note the firm's EPS Estimate Next Year, which forecasts a loss of $2.46 per share. In conclusion, while Rhythm Pharmaceuticals carries some risk, its strong financial health and potential for growth could make it a worthwhile consideration for investors looking for opportunities in the biotechnology sector. However, it is advisable to consider the company's high Probability Of Bankruptcy and expected losses in the coming year. .
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Nico Santiago do not own shares of Rhythm Pharmaceuticals. Please refer to our Terms of Use for any information regarding our disclosure principles.